COMPASS Pathways plc (CMPS)
| Market Cap | 1.66B +177.6% |
| Revenue (ttm) | n/a |
| Net Income | -394.19M |
| EPS | -3.61 |
| Shares Out | 138.48M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,282,987 |
| Open | 11.69 |
| Previous Close | 11.47 |
| Day's Range | 11.42 - 12.08 |
| 52-Week Range | 4.88 - 15.87 |
| Beta | 2.56 |
| Analysts | Strong Buy |
| Price Target | 23.75 (+97.92%) |
| Est. Earnings | Nov 3, 2026 |
About CMPS
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in L... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for CMPS stock is "Strong Buy." The 12-month stock price target is $23.75, which is an increase of 97.92% from the latest price.
News
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, ...
Compass Pathways names Kelley Boucher as Chief People Officer
Compass Pathways (CMPS) announced the appointment of Kelley Boucher as Chief People Officer, effective September 30. This appointment strengthens the Compass executive team as the company continues to...
Compass Pathways Appoints Kelley Boucher as Chief People Officer
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, ...
COMPASS Pathways Transcript: TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
Phase III data for COMP360 in treatment-resistant depression show durable, incremental benefits with additional doses and a strong safety profile. NDA filing is on track for Q4, with launch readiness by year-end and broad commercial site preparedness. Most states will reschedule rapidly post-approval, and robust training, reimbursement, and support systems are in place.
COMPASS Pathways Transcript: Deutsche Bank 2026 Healthcare Summit
COMP360 is on track for FDA submission in Q4 2026 and potential launch in H1 2027 for TRD, with strong clinical results, positive payer feedback, and robust commercial preparation. The product offers a differentiated profile versus SPRAVATO, and expansion into PTSD and other neuropsychiatric indications is underway.
COMPASS Pathways Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
A novel psychedelic therapy for treatment-resistant depression is nearing FDA approval, with rapid and durable efficacy shown in phase III trials and a launch targeted for the first half of 2027. Strong payer interest, robust infrastructure, and a large unmet patient need support significant market potential, while a major PTSD program is also advancing.
Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, ...
COMPASS Pathways Transcript: H.C. Wainwright 28th Annual Global Investment Conference
COMP360 showed rapid, durable efficacy in TRD with just one to four annual doses, and open-label data support sustained benefits up to a year. Regulatory review is accelerated, with launch readiness by end of 2026 and commercial launch expected in early 2027. The PTSD program is advancing and may represent an even larger opportunity.
Compass Pathways Launches ‘Change the Tune in TRD' in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, ...
Strata Mental Health Solutions awarded training grant by Compass Pathways
Strata Mental Health Solutions announced it has been awarded one of the five U.S. HCP training grants awarded by Compass Pathways (CMPS) to develop U.S. health care provider training programs…
Strata Mental Health Solutions Awarded U.S. Healthcare Provider Training Grant from Compass Pathways to Develop Provider Training for COMP360
ATLANTA--(BUSINESS WIRE)--Strata Mental Health Solutions, the expert-led training and implementation partner preparing clinical networks to deliver psychedelic treatments, today announced it has been ...
Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training
New certificate program will prepare clinicians to support patients receiving COMP360 psilocybin treatment, if approved by the FDA NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Fluence, a leading provider ...
Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, ...
Compass Pathways to Participate in Investor Conferences the Week of September 14th
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, ...
Compass Pathways Forecast: Breakout Could Target $22.51–$25.51
CMPS is testing a breakout after positive Phase 3 data, with a close above $15.40 potentially opening the way toward $22.51–$25.51.
COMPASS Pathways Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
COMP360 is progressing through FDA review for TRD, with launch targeted for early 2027 and a differentiated profile versus existing therapies. Commercial planning leverages new reimbursement codes, streamlined site logistics, and patient support, while expansion into PTSD addresses a significant unmet need.
Compass Pathways reports 52-week results from Phase 3 COMP005 trial
Compass Pathways (CMPS) announced the topline 52-week results (Part C) from its Phase 3 COMP005 trial of COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression...
Compass Pathways' New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, ...
Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, ...
Compass Pathways Recognized as a 2026 Fierce 50 Breakthrough Honoree
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways, a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, has been named a 20...
Compass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, ...
COMPASS Pathways Transcript: Canaccord Genuity's 46th Annual Growth Conference
COMP360 is advancing toward a Q4 NDA filing, with FDA review and DEA rescheduling expected to enable a first-half 2027 launch. The product offers rapid, durable relief for treatment-resistant depression, with a favorable safety profile and strong payer interest. A late-stage PTSD program is also progressing.
Compass Pathways price target lowered to $65 from $70 at H.C. Wainwright
H.C. Wainwright analyst Patrick Trucchio lowered the firm’s price target on Compass Pathways (CMPS) to $65 from $70 and keeps a Buy rating on the shares. The firm moderated the…
Compass Pathways price target raised to $18 from $17 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Compass Pathways (CMPS) to $18 from $17 and keeps an Overweight rating on the shares.
Psychedelic: Compass Pathways, GH Research report quarterly earnings
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a DSMB approval and a CEO appointment. EARNINGS: On Thursday, GH…